Similar to the risk of rash for all grades in Group B, the risk of developing rash was significantly higher than that of the control chemotherapy group [27, 36, 38, 41, 45, 53, 66, 73–75, 79, 80, 84, 86, 96, 101, 103, 107, 111, 112], when PD-1 or PD-L1 was given together with chemotherapy (OR = 2.61, 95% CI: [1.67, 4.08]; I2 = 0%, Z = 4.20, p < 0.0001; Figure 6(b)), especially for ovarian cancer (OR = 4.34, 95% CI: [1.89, 9.96]; I2 = 0%, Z = 3.46, p=0.0005; Figure 6(b)) [96, 101, 103]. The gene discussed is PDCD1; the disease is ovarian carcinoma.